Gracell Biotechnologies Inc.
Gracell Biotechnologies Inc. (GRCL) Revenue
Annual & quarterly revenue history · segment & region breakdown
GRCL · revenue · updated Jun 9, 2026
Core revenue metrics
Trailing 12 monthsGracell Biotechnologies Inc. trailing twelve-month (TTM) revenue is $0.00B, a decrease of 100.00% year-over-year from $0.00B in FY2022.
Revenue trend
2022 – 2018 · AnnualRevenue history
| Fiscal year end | Revenue | Change | Growth |
|---|---|---|---|
| 2022-12-31 | $0.00B | -$0.00B | -100.00% |
| 2021-12-31 | $0.00B | +$0.00B | — |
| 2020-12-31 | $0.00B | +$0.00B | — |
| 2019-12-31 | $0.00B | +$0.00B | — |
| 2018-12-31 | $0.00B | — | — |
Compare revenue vs peers
BiotechnologyCompare GRCL revenue against listed peers. Click any row to open that company's revenue tab.
About Revenue & Reporting
Revenue (also called sales, net sales, or turnover) is the total income Gracell Biotechnologies Inc. receives from its business operations before deducting any costs or expenses. It is the top line of the income statement. Unlike net income or earnings, revenue does not account for operating costs, taxes, interest, or depreciation.
Gracell Biotechnologies Inc. reports revenue on a fiscal year ending Dec 31 basis under US GAAP, denominated in CNY.
Data sourced from Gracell Biotechnologies Inc.'s 10-K and 10-Q SEC filings via Financial Modeling Prep.
Frequently asked questions
GRCL revenue · 4 questionsGRCL's trailing twelve-month (TTM) revenue is $0.00B. That is a decrease of 100.00% year-over-year from $0.00B in FY2022.
▸ Source: FMP · Gracell Biotechnologies Inc. SEC filings · GAAP · Gracell Biotechnologies Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026